Last reviewed · How we verify
NCT06840067
Clinical Study of Carbon Ion Radiotherapy for Pancreatic Cancer.
NA trial testing carbon ion radiotherapy (CIRT) in Pancreatic Cancer Metastatic in 62 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | Gansu Wuwei Tumor Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 62 |
| Start date | 1 March 2025 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- carbon ion radiotherapy (CIRT)
Conditions studied
- Pancreatic Cancer Metastatic — all drugs for Pancreatic Cancer Metastatic →
- Pancreatic Cancer Non-resectable — all drugs for Pancreatic Cancer Non-resectable →
Sponsor
Gansu Wuwei Tumor Hospital
Who can join
Adults 18 to 80, any sex, with Pancreatic Cancer Metastatic or Pancreatic Cancer Non-resectable. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective is to evaluate the efficacy and safety of carbon ion radiotherapy (CIRT) combined with nituzumab and gemcitabine in the treatment of locally advanced and metastatic pancreatic cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06840067
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreatic Cancer Metastatic
Currently open trials in the same condition.
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07040228 — A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Tr · Phase 1, PHASE2 · recruiting
- NCT06752811 — Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer · Phase 3 · recruiting
- NCT06946420 — SENECA: First Line metaStatic pancrEatic caNcer Primary and Distant (if Oligometastatic) lEsion direCted rAdiotherapy · Phase 3 · active not recruiting
- NCT06168812 — A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer · Phase 2 · active not recruiting
Other Gansu Wuwei Tumor Hospital trials
Trials by the same sponsor.
- NCT06831773 — Clinical Study of Carbon Ion Radiotherapy for High-grade Glioma · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06840067 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gansu Wuwei Tumor Hospital
- Last refreshed: 25 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06840067.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing